Federated Hermes
SNDX icon

Federated Hermes’s Syndax Pharmaceuticals SNDX Stock Holding History

Federated Hermes’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-937,250
Closed -$18M – 2179
2024
Q3 		$18M Buy
937,250
+281,000
+43% +$5.81M 0.04% 451
2024
Q2 		$13.5M Buy
656,250
+117,536
+22% +$2.46M 0.03% 479
2024
Q1 		$12.8M Buy
+538,714
New +$12M 0.03% 517
2020
Q2 		– Sell
-67
Closed -$1K – 2365
2020
Q1 		$1K Sell
67
-313
-82% -$2.94K ﹤0.01% 2149
2019
Q4 		$3K Sell
380
-248
-39% -$1.82K ﹤0.01% 2004
2019
Q3 		$5K Sell
628
-70
-10% -$638 ﹤0.01% 1953
2019
Q2 		$6K Buy
698
+125
+22% +$911 ﹤0.01% 1963
2019
Q1 		$3K Hold
573
– – ﹤0.01% 2041
2018
Q4 		$3K Buy
573
+105
+22% +$576 ﹤0.01% 2051
2018
Q3 		$4K Buy
468
+241
+106% +$1.72K ﹤0.01% 2090
2018
Q2 		$2K Sell
227
-258
-53% -$2.53K ﹤0.01% 2115
2018
Q1 		$7K Buy
+485
New +$5.15K ﹤0.01% 1930

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Federated Hermes's SNDX Position: Q4 2024 in Review

Federated Hermes sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 937,250 shares — an estimated $18M sold.

Federated Hermes first reported a position in SNDX in Q1 2018 and held it in 12 quarters. The position peaked at $18M in Q3 2024. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • Federated Hermes reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 937,250 Syndax Pharmaceuticals shares in Q4 2024, an estimated $18M.
  • Federated Hermes first reported a position in Syndax Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • Federated Hermes's Syndax Pharmaceuticals position peaked at $18M in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.